American BioMed Inc. Announces New Distribution Agreements.

THE WOODLANDS, Texas--(BUSINESS WIRE)--Dec. 3, 1996-- American BioMed Inc. (OTC Bul-Bd:ABMI), of The Woodlands, today announced that it has entered into agreements with several global distribution companies.

Micor, Inc., an international medical product distributor in Pittsburgh, Pa. and A. Vassiliou, headquartered in Athens, Greece, are two of the companies named which will provide market access for the company's product lines. The company has presently signed agreements with 22 new distribution partners in 1996 which represent major global markets in the U.S., Australia, China, Germany, Argentina, Greece, Mexico, Taiwan and the Caribbean.

Arthur S. Przybyl, vice president of sales and marketing, remarked "Our efforts to date have created a new customer base in several countries for our products. As part of our strategy we will continue to aggressively pursue new global distribution partners and will work toward increasing revenue streams through our existing distribution network. I believe these efforts will produce very positive results in 1997."

Company President and CEO, Steven B. Rash stated, "the Company is very pleased with the progress shown in all areas of its operations. Current commercialization efforts are proving successful and are reflected in our revenue growth over the last two quarters. We anticipate this growth to significantly improve in fiscal 1997 and beyond. Additionally, phase II clinical trials for the OmniCath(R) are continuing and have shown successful results thus far. Our confidence level is very high and we anticipate an approval for the device by late-third or early-fourth quarter in 1997. Finally, I believe the Company's annual shareholder meeting held on November 22, was an overall success. We were very pleased to have the opportunity to meet and address important concerns of our shareholders who were in attendance. The confidence exuded for present management's efforts from our shareholders and their overwhelming support and approval by vote of each item presented in the shareholder proxy statement, confirms our belief in the business strategy we have adopted. Management will continue to work very diligently in developing business relationships which will further enhance our exposure in the minimally invasive healthcare industry."

American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. The devices include but are not limited to the OmniCath(R) atherectomy catheter, as well as the company's nine patented FDA approved unique all-silicone balloon catheters. These consist of thermodilution, embolectomy and bi-lumen irrigation, urinary bladder and angioscopy catheters. The OmniStent(TM) and accompanying stent technology is used to support diseased blood vessels. Other devices such as the company's drug delivery catheters, guidewire microfilter and minimally invasive spinal instruments are also under development.

CONTACT: Thomas E. Waite & Associates Inc.

Phone: [phone] Fax: [phone]

email: [e-mail]

or

http://www.americanbiomed.com/